Neurogenic effects of fingolimod in hippocampus, affecting fear memory.
Fingolimod (FTY720; Gilenya™,Novartis Pharma AG) is a recently developed Sphingosine-1-Phosphate (S1P) analogue, orally administered as a new therapeutic agent in Multiple Sclerosis (MS) (Brinkmann V. et al. 2010). S1P receptors (S1PRs) are expressed in various sites in the CNS including the subven...
| Автори: | , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Frontiers Media S.A.
2014-05-01
|
| Серія: | Frontiers in Systems Neuroscience |
| Предмети: | |
| Онлайн доступ: | http://journal.frontiersin.org/Journal/10.3389/conf.fnsys.2014.05.00002/full |